Table 3 KEGG pathway enrichment analysis for the differentially expressed mRNAs
Category | Term | Description | Count | P-value |
|---|---|---|---|---|
pathway | hsa04380 | Osteoclast differentiation | 8 | 3.13E-04 |
pathway | hsa04610 | Complement and coagulation cascades | 6 | 6.00E-04 |
pathway | hsa05150 | Staphylococcus aureus infection | 5 | 2.01E-03 |
pathway | hsa04115 | p53 signaling pathway | 5 | 4.42E-03 |
pathway | hsa04940 | Type I diabetes mellitus | 4 | 8.38E-03 |
pathway | hsa04611 | Platelet activation | 6 | 9.55E-03 |
pathway | hsa05322 | Systemic lupus erythematosus | 6 | 1.08E-02 |
pathway | hsa04512 | ECM-receptor interaction | 5 | 1.11E-02 |
pathway | hsa04672 | Intestinal immune network for IgA production | 4 | 1.14E-02 |
pathway | hsa05200 | Pathways in cancer | 10 | 1.60E-02 |
pathway | hsa04151 | PI3K-Akt signaling pathway | 9 | 2.14E-02 |
pathway | hsa05145 | Toxoplasmosis | 5 | 2.42E-02 |
pathway | hsa05202 | Transcriptional misregulation in cancer | 6 | 2.56E-02 |
pathway | hsa05140 | Leishmaniasis | 4 | 3.40E-02 |
pathway | hsa05310 | Asthma | 3 | 3.60E-02 |
pathway | hsa05332 | Graft-versus-host disease | 3 | 4.29E-02 |
pathway | hsa05020 | Prion diseases | 3 | 4.53E-02 |